ARTICLE | Company News

Alimera gains on Iluvien approval

September 30, 2014 2:30 AM UTC

Alimera Sciences Inc. (NASDAQ:ALIM) added $0.41 to $5.33 on Monday after FDA approved Iluvien fluocinolone acetonide intravitreal implant to treat diabetic macular edema in patients who have been previously treated with corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP). ...